JGJean-Jacques Goy

Jean-Jacques Goy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Jacques Goy has a total of 208 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of Postoperative Continuous Wireless Cardiac Rhythm Monitoring with Traditional Telemetry in Cardiac Surgery Patients: the SMART-TEL Study

    by Julien Pidoux, Emilie Conus, Naomi Blackman, Javier Orrit, Gregory Khatchatourov, Patrick Ruchat, Serban Puricel, Stéphane Cook, Jean-Jacques Goy

    Comparison of Postoperative Continuous Wireless Cardiac Rhythm Monitoring with Traditional Telemetry in Cardiac Surgery Patients: the SMART-TEL Study


  • Open Access

    Automatic Double Check Monitoring of Continuous Fluid Excretion and Urine Output

    by Nicolas Goy, Philippe Beuret, Alexandre Despond, Reza Porouchani, Jean-Jacques Goy

    Background: Nowadays vital signs in clinics are electronically monitored excepted for urine output which still requires, manual recording, which is subject to human errors. We, in-vitro, assessed in this study the ability a novel electronic device to measure by a combination of two different methods, the real time flow-output, like urine output. Methods: Flow or urine output was measured by a combination technique of gravimetry using a dynamometer and capacitive sensing to improve precision. Data were obtained in 3 different situations, low, medium, and high flow. Results: Three different situations were tested: full or empty dead space and Pasteur’s chamber. The differences between the injected and measured volume varies from 0 to 5 ml representing a maximal error of 3 % regardless of the volume injected and the flow in ml/hour. The capacitive sensors behave as expected with a parallel curve of the expected and measured flow. Conclusion: We have shown in this in-vitro study that the combination of gravimetry and capacitive sensors analysis allow accurate measurement of volume and flow-output. Clinical trials should be conducted to confirm its usefulness in urine output measurement in the real life.

  • Open Access

    Performance of the new SmartCardia wireless, wearable oximeter: a comparison with arterial SaO2 in healthy volunteers

    by Francisco Rincon, Julien Pidoux, Srini Murali, Jean-Jacques Goy

    Background: Our goal was to evaluate the performance of a new wearable arm located pulse oximeter. Methods: Twelve volunteers were monitored with three pulse oximeters and underwent desaturation to 70% SaO2. We compared the accuracy of SpO2 reading from the SmartCardia system with SpO2 using two well established devices (Masimo and Nellcor) as reference. Oximetry was performed at different level of oxygen saturation varying from 70 to 100%. Bias, ARMS and precision were evaluated using Bland-Altman plots. Results: The mean (SD) differences between SaO2 compared to SpO2 and the devices were as follows: SaO2 versus Masimo 2,12 ± 1,01% (95% CI 1,45 to 2,79), SaO2 versus Nellcor 0,78 ± 0,58% (95% CI − 0,29 to 1,65) and SaO2 versus SmartCardia 0,42 ± 0,24% (95% CI − 0,64 to 1,46). The bias between SmartCardia, Masimo, Nellcor devices and SaO2 was 0.16 (95% CI 0.05 to 0.33) and LoA (level of agreements) 2.96 (95% CI − 2,68 to 2,89) for SmartCardia, 2,02 (95% CI 1,49 to 2,54) and LoA − 6 to 11 for Masimo, and 0,76 (95% CI 0,5 to − 1) and LoA − 3,5 to 5,0 for Nellcor. ARMS for the 70–100% SaO2 range was 1,4 for SmartCardia, 5,0 for Masimo and 2,31 for Nellcor. Conclusions: The new wireless SmartCardia SpO2 measurement system demonstrated in-line results, bias, ARMS and precision in healthy volunteers, when compared with the gold standard SaO2 and with two well established systems, Masimo and Nellcor. Trial registration: The present trial was prospectively registered at UCSF record (registration number:10–00437), on March 8, 2021.


  • Open Access

    Performance of the new SmartCardia wireless, wearable oximeter: a comparison with arterial SaO2 in healthy volunteers.

    by Francisco Rincon, Julien Pidoux, Srini Murali, Jean-Jacques Goy

    Backgroud: Our goal was to evaluate the performance of a new wearable arm located pulse oximeter.Methods: Twelve volunteers were monitored with three pulse oximeters and underwent desaturation to 70% SaO2 . We compared the accuracy of SpO 2 reading from the SmartCardia system with SaO2 using two well established devices (Masimo and Nellcor ) as reference.Oximetry was performed at different level of oxygen saturation varying from 70 to 100%. Bias, ARMS and precision were evaluated using Bland-Altman plots.Results: The mean (SD) differences between SpO2 compared to SaO2 and the devices were as follows: SaO2 versus Masimo 2,12±1,01% (95% CI 1,45 to 2,79), SaO2 versus Nellcor 0,78±0,58 % (95 % CI -0,29 to 1,65) and SaO2 versus SmartCardia 0,42±0,24 % (95% CI -0,64 to 1,46). The bias between SmartCardia, Masimo, Nellcor devices and SaO2 was 0.16 (95% CI 0.05 to 0.33) and LoA (level of agreements) 2.96 (95% CI -2,68 to 2,89) for SmartCardia, 2,02 (95% CI 1,49 to 2,54) and LoA -6 to 11 for Masimo, and 0,76 (95% CI 0,5 to -1) and LoA -3,5 to 5,0 for Nellcor. ARMS for the 70-100% SaO 2 range was 1,4 for SmartCardia, 5,0 for Masimo and 2,31 for Nellcor.Conclusions: The new wireless SmartCardia SpO2 measurement system demonstrated in-line results, bias, ARMS and precision in healthy volunteers, when compared with the gold standard SaO2 and with two well established systems, Masimo and Nellcor.Trial registration: The present trial was prospectively registered at UCSF record (registration number:10-00437), on March 8, 2021.

  • Open Access

    Chest Pain and Hemodynamic Instability in a Young Woman

    by Nikesh Raj Shrestha, Stéphane Cook, Jean-Jacques Goy

  • Open Access

    Short-term outcomes of aortic valve neocuspidization for various aortic valve diseases

    by Gregory Khatchatourov, Mathieu van Steenberghe, Doris Goy, Mathieu Potin, Javier Orrit, François Perret, Nicolas Murith, Jean-Jacques Goy


  • Open Access

    Five‐year angiographic,OCTand clinical outcomes of a randomized comparison of everolimus and biolimus‐eluting coronary stents with everolimus‐eluting bioresorbable vascular scaffolds

    by Sara Schukraft, Diego Arroyo, Mario Togni, Jean‐Jacques Goy, Peter Wenaweser, Mathieu Stadelmann, Gerard Baeriswyl, Olivier Muller, Jean‐Christophe Stauffer, Serban Puricel, et al.

    Aims: To compare 5‐year angiographic, optical coherence tomography (OCT), and clinical outcomes between patients treated with bioresorbable vascular scaffolds (BVS) and drug‐eluting stents (DES).Methods: The EverBio‐2 trial (Comparison of Everolimus‐ and Biolimus‐Eluting Coronary Stents with Everolimus‐Eluting Bioresorbable Vascular Scaffold) was a single‐center, assessor‐blinded, randomized controlled trial in which 240 patients were randomly allocated (1:1:1) to BVS, everolimus‐eluting (EES) or biolimus‐eluting (BES) DES. Clinical follow‐up was scheduled up to 5 years. All patients, alive and who did not have repeat revascularization of the target lesion during follow‐up were asked to return for angiographic follow‐up at 5 years.Results: Five‐year angiographic follow‐up was completed in 122 patients (51%) and OCT analysis was performed in 86 (36%) patients. In‐stent late lumen loss was similar in both groups with 0.50 ± 0.38 mm in BVS versus 0.58 ± 0.36 mm in EES/BES,p = 0.20. Clinical follow‐up was complete in 232 patients (97%) at 5 years. The rate of the device‐oriented endpoint was 22% in the BVS and 18% in the EES/BES group (p = 0.49). The patient‐oriented composite endpoint occurred in 40% of BVS‐ and 43% of EES/BES‐treated patients (p = 0.72) at 5 years. No acute coronary syndrome due to stent thrombosis was detected after 2 years. Complete BVS strut resorption was observed at 5 years in the OCT subgroup.Conclusion: Five‐year clinical outcomes were similar between BVS and DES patients as well as angiographic outcomes in a selected subgroup. However, a definitive conclusion cannot be drawn because the EverBio‐2 trial was not powered for clinical and angiographic endpoints at 5 years of follow‐up.


  • Des paresthésies d’un doigt

    by L. Morel, J.-J. Goy

  • Radial Aneurysmal AV Fistula as a Complication of Coronary Angioplasty

    by Jean-Jacques Goy, Francine Tinguely, Jean-Baptiste Zerlauth, Gregory Khatchatourov


  • Open Access

    Cardiac Ambulatory Monitoring: New Wireless Device Validated Against Conventional Holter Monitoring in a Case Series

    by Srinivasan Murali, Nicolas Brugger, Francisco Rincon, Manoj Mashru, Stéphane Cook, Jean-Jacques Goy

    Background: Cardiac arrhythmias are very common but underdiagnosed due to their transient and asymptomatic nature. An optimization of arrhythmia detection would permit to better treat patients and could substantially reduce morbidity and mortality. The SmartCardia ScaAI wireless patch is a novel CE IIa approved, single-lead electrocardiographic (ECG) ambulatory monitor designed for cardiac arrhythmias detection.Hypothesis: The accuracy of the new SmartCardia wireless patch to detect arrhythmias is comparable to the conventional Holter monitoring.Methods: Patients referred for a suspicion of arrhythmia between February and March 2020 were included in the trial. Simultaneous ambulatory ECG were recorded using a conventional 24-h Holter and the SmartCardia. The primary endpoint was the detection of cardiac arrhythmias over the total wear time of the devices, defined as premature atrial contraction (PAC), supraventricular tachycardia ≥3 beats, premature ventricular contraction (PVC), and ventricular tachycardia ≥3 beats. Conduction abnormalities, pause ≥2 s and atrioventricular block (AVB), were also tracked. McNemar's test was used to compare the matched pairs of data from both devices.Results: A total of 40 patients were included in the trial. Over the total wear time, there was no significant difference between the devices for ventricular and supraventricular arrhythmias detection. Pauses and AVB were equally identified by the two devices in three patients.Conclusion: Over the total wear time, the SmartCardia device showed an accuracy to detect arrhythmia similar to the 24-h Holter monitoring: single-lead, adhesive-patch monitoring might become an interesting alternative to the conventional Holter monitoring.